Mirae Asset Global Investments Co. Ltd. Buys New Shares in Jazz Pharmaceuticals PLC $JAZZ

Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the third quarter, Holdings Channel.com reports. The firm purchased 3,317 shares of the specialty pharmaceutical company’s stock, valued at approximately $768,000.

Several other hedge funds have also made changes to their positions in JAZZ. Bank of New York Mellon Corp boosted its stake in Jazz Pharmaceuticals by 44.5% in the 1st quarter. Bank of New York Mellon Corp now owns 1,679,371 shares of the specialty pharmaceutical company’s stock worth $317,485,000 after purchasing an additional 517,514 shares during the period. Tri Locum Partners LP purchased a new position in Jazz Pharmaceuticals during the 1st quarter worth approximately $29,995,000. Bank of America Corp DE raised its stake in Jazz Pharmaceuticals by 10.9% during the 1st quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company’s stock valued at $191,848,000 after purchasing an additional 99,656 shares during the period. Amundi raised its stake in Jazz Pharmaceuticals by 2,445.3% during the 1st quarter. Amundi now owns 55,640 shares of the specialty pharmaceutical company’s stock valued at $10,519,000 after purchasing an additional 53,454 shares during the period. Finally, Rokos Capital Management LLP acquired a new stake in Jazz Pharmaceuticals during the 1st quarter valued at $9,833,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on JAZZ. Royal Bank Of Canada increased their target price on Jazz Pharmaceuticals from $296.00 to $305.00 and gave the company an “outperform” rating in a report on Tuesday, November 3rd. The Goldman Sachs Group began coverage on Jazz Pharmaceuticals in a report on Thursday, September 24th. They set a “buy” rating and a $337.00 price target on the stock. Barclays upped their price target on Jazz Pharmaceuticals from $271.00 to $275.00 and gave the company an “overweight” rating in a research report on Tuesday, November 3rd. Morgan Stanley increased their price objective on Jazz Pharmaceuticals from $314.00 to $319.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 3rd. Finally, Piper Sandler increased their price objective on Jazz Pharmaceuticals from $301.00 to $310.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 4th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $293.45.

Key Stories Impacting Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz beat quarterly estimates, reporting $1.24 billion in revenue versus roughly $1.21 billion expected, with revenue up 10.4% year over year. Coverage also reported that the company raised its 2026 revenue outlook to approximately $4.78 billion–$4.85 billion, helping reinforce the growth outlook. Q3 results and outlook
• Positive Sentiment: RBC, Barclays, Morgan Stanley and JPMorgan issued favorable commentary or raised price targets after the results. The analyst optimism adds support to the stock’s post-earnings momentum. Barclays price-target update
• Neutral Sentiment: CEO Renée Galá sold 1,000 shares under a pre-arranged Rule 10b5-1 plan and retained 140,394 shares. Director Bruce Cozadd also sold 6,000 shares under a pre-arranged plan, while CAO Patricia Carr sold 1,413 shares and retained 6,512. These sales may draw investor attention, but planned transactions are not necessarily a signal about near-term business prospects. Insider transaction coverage

Jazz Pharmaceuticals Price Performance

JAZZ stock opened at $234.76 on Monday. The company has a 50 day moving average of $229.39 and a two-hundred day moving average of $217.74. The company has a market cap of $15.07 billion, a price-to-earnings ratio of 79.85, a PEG ratio of 0.43 and a beta of 0.38. Jazz Pharmaceuticals PLC has a 12-month low of $128.80 and a 12-month high of $266.38. The company has a quick ratio of 1.64, a current ratio of 1.82 and a debt-to-equity ratio of 1.09.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) EPS for the quarter, beating the consensus estimate of ($4.03) by $0.15. Jazz Pharmaceuticals had a net margin of 4.37% and a return on equity of 16.88%. The business had revenue of $1.24 billion for the quarter, compared to analysts’ expectations of $1.21 billion. During the same period in the previous year, the company posted $8.13 EPS. Jazz Pharmaceuticals’s revenue was up 10.4% on a year-over-year basis. On average, equities analysts anticipate that Jazz Pharmaceuticals PLC will post 11.08 earnings per share for the current fiscal year.

Insider Activity

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 1,413 shares of the business’s stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $231.36, for a total value of $326,911.68. Following the transaction, the chief accounting officer owned 6,512 shares in the company, valued at $1,506,616.32. The trade was a 17.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Renée Galá sold 1,000 shares of the company’s stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $225.37, for a total value of $225,370.00. Following the completion of the transaction, the chief executive officer directly owned 140,394 shares in the company, valued at approximately $31,640,595.78. The trade was a 0.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 102,534 shares of company stock valued at $25,185,243. 4.10% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets.

Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.

Jazz expanded its portfolio through acquisitions, including the 2021 acquisition of GW Pharmaceuticals, which added Epidiolex and other cannabinoid-based medicines.